fda warning letters glp-1 compounding october 2025 Sends 30 To Continue Clampdown on Compounded GLP-1s FDA Issues 30 Warning Letters

The evidence doesnt confirm most severe risks, but careful monitoring and patient education are essential to maximize benefit and minimize harm

When to decrease dose Consider decreasing if: Persistent side effects that don't resolve Excellent results achieved and maintenance desired Budget constraints require conservation Stacking and wanting to optimize ratios Many researchers find they can reduce dose during maintenance phases after achieving initial goals during more intensive loading phases

While the optimal position is lying face down while being bent at the hips, this may not be feasible outside of an operating room

Most studies showed good reporting quality implying an overall low risk of bias (Supplementary table)